	US 7,332,480 B2
	Compositions for the regulation of cytokine activity
Irun R. Cohen, Rehovot (Israel); Ofer Lider, Rehovot (Israel); Liora Cahalon, Givataim (Israel); Oded Shoseyov, Shimshon (Israel); and Raanan Margalit, Rehovot (Israel)
Assigned to Yeda Research and Development Co. Ltd., Rechovot (Israel)
Filed on Apr. 26, 2004, as Appl. No. 10/831,288.
Application 10/831288 is a division of application No. 09/495723, filed on Feb. 01, 2000, granted, now 6,750,207.
Application 09/495723 is a division of application No. 08/486127, filed on Jun. 07, 1995, granted, now 6,020,323.
Application 08/486127 is a continuation in part of application No. 08/436330, granted, now 5,861,382, previously published as PCT/US93/10868, filed on Nov. 09, 1993.
Application 08/436330 is a continuation in part of application No. 08/096739, filed on Jul. 23, 1993, abandoned.
Application 08/096739 is a continuation in part of application No. 07/974750, filed on Nov. 10, 1992, abandoned.
Application 07/974750 is a continuation in part of application No. 07/878188, filed on May 01, 1992, abandoned.
Prior Publication US 2004/0198697 A1, Oct. 07, 2004
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/7016 (2006.01); A61K 31/727 (2006.01); C08B 37/10 (2006.01)

U.S. Cl. 514—53 [514/56; 536/21; 536/123.13]

19 Claims

1. A method for treating an inflammatory disease or disorder, comprising administering a pharmaceutically effective amount of a therapeutic agent to a subject in need thereof, said therapeutic agent comprising:

an N-sulfated 4-deoxy-4-en-iduronoglucosamine containing at least one additional sulfate group or a pharmaceutically acceptable salt thereof, or an N-acetylated 4-deoxy-4-en-iduronoglucosamine containing at least two sulfate groups or a pharmaceutically acceptable salt thereof; and

a pharmaceutically acceptable carrier.